Navigation Links
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Date:11/10/2008

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at

the ASH Meeting December 6-9, 2008

COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.

In addition, two abstracts on pre-clinical ofatumumab data have been accepted for presentation at poster sessions. All three ofatumumab abstracts are available on the ASH website at http://www.hematology.org.

ASH Sessions

Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial.

Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers.

Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on t
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genmab Announces Results for the First Nine Months of 2008
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
4. Genmab A/S - Changes Board/Management/Auditors
5. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
6. Genmab Announces 2008 First Quarter Results
7. Passing of Genmab A/S Annual General Meeting
8. Genmab A/S - Notice to Convene Annual General Meeting
9. Genmabs 2007 Annual Report
10. Genmab Announces Year End 2007 Financial Results
11. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Sonia Moralejo Garca at the University of the Basque Country ... and other magnetic devices of wide industrial application. , It ... that are ever smaller and that nanotechnology, although it its ... in our society. Who has not heard of nanotubes, nanoparticles ...
... INCREASE 14.6%. Q4 2007 DILUTED EPS UP 20.8% TO $.64. 2008 ... $2.62 PER SHARE., ST. LOUIS, Feb. 12 , HIGHLIGHTS: ... -- Q4 2007 Sales Set New Quarterly Record: At $532.1 ... high, beating the Q2 2007 record of $507.5 ...
... of Dow AgroSciences Announces Milestone in Wall Street ... ,Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: ... a key research milestone as part of,their joint ... successful application of Sangamo,s zinc finger DNA-binding,protein nuclease ...
Cached Biology Technology:A researcher of UPV/EHU has designed nanomagnets for industry 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 3Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 4Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 5Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 6Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 7Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 8Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 9Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 10Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 11Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 12Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 13Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 14Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 15Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 16Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 17Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 18Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 19Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 20Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 2Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 3Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 4
(Date:5/18/2013)... FL (May 18, 2013) Research presented at ... managing digestive health through diet and lifestyle. ... plagued by reduced muscle strength, fatigue and poor ... when patients are in remission. A randomized, double ... that vitamin D supplementation corresponded to significant relief ...
(Date:5/17/2013)... provide the white noise of the South, but the night ... Southern air hangs heavy from the humidity and the sounds ... 140 species of frogs, toads and salamanders, is the center ... and swamps are the auditorium for their symphonic choruses, the ... Initiative, or ARMI, have front-row seats. , Amphibians, ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4SUMO wrestling cells reveal new protective mechanism target for stroke 2
... A new study, led by Felix Aigner, M.D., ... as potentially responsible for regulating the body's inflammatory ... complications involved with many transplantations is the damage ... following surgery, known as ischemia and reperfusion (IR). ...
... major role in deadly prion diseases by smashing up ... allow fatal brain illnesses to quickly spread, new Brown ... say, because they might reveal a way to control ... drug could be made that inhibits this fragmentation process, ...
... The costs due to complications from preterm birth are ... preterm infants are estimated to be almost $2 billion ... researchers found that giving nitroglycerin to mothers who had ... baby’s health. The results of the study are reported ...
Cached Biology News:Brown team finds crucial protein role in deadly prion spread 2
...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Request Info...
NATIVE RAT OSTEOCALCIN...
Biology Products: